REDUCE-IT HF analyses show Vascepa driven serum EPA levels that suggest potential benefits in new heart failure - Amarin Corp
Related news and insights
Amarin Corporation announced the presentation of REDUCE-IT HEART FAILURE (HF) data. The REDUCE-IT HF analyses examined the effects of Vascepa (icosapent ethyl) on the incidence of new heart failure by achieved on-treatment serum EPA levels in REDUCE-IT patients.
Amarin Corporation announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Great Britain Marketing Authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (at least 150 mg/dL) and either established cardiovascular disease or diabetes, and at least one additional cardiovascular risk factor.